Physician profile
Sarmad Said
NPI 1912266511
$4,025.76
in general payments reported to CMS, 2019-2025
18 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $179 · 2021: $424 · 2022: $522 · 2023: $697 · 2024: $604 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,676.09 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, Sq-Rx Pulse Generator |
| Janssen Pharmaceuticals, INC | $226.69 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.57 | 2019-2023 | Lifevest |
| Abbott Laboratories | $159.50 | 2019-2022 | |
| Edwards Lifesciences Corporation | $158.83 | 2019 | |
| Atricure, INC. | $124.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.15 | 2019-2021 | |
| Biosense Webster, INC. | $88.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.84 | 2019 | |
| Amgen INC. | $47.89 | 2023-2024 | Repatha |
| Biotronik INC. | $43.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.79 | 2020 | |
| Merck Sharp & Dohme LLC | $19.33 | 2024 | Verquvo |
| Braemar Manufacturing, LLC | $17.94 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $15.28 | 2022 | |
| Pfizer INC. | $13.17 | 2020 | |
| Infobionic, INC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarmad Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.